Summary
A paucity of information is available concerning the use of levodopa and carbidopa during pregnancy. Particularly lacking is whether these agents cross the placenta and whether levodopa undergoes metabolism in the fetus. The present study carried out in aborted fetal tissues demonstrates that levodopa crosses the placental barrier and suggests that it may be metabolized in fetal tissues, including the brain and spinal cord. The possibility exists that early exposure to levodopa or dopamine may alter the normal neuronal development in the fetus, and caution in the use of levodopa during pregnancy should be observed.
This is a preview of subscription content, log in via an institution to check access.
References
Cook DK, Klawans HL (1985) Levodopa during pregnancy. Clin Neuropharmacol 8: 93–95
Golbe L (1987) Parkinson's disease and pregnancy. Neurology 37: 1245–1249
Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16: 233–240
Mytilineou C, Han S-K, Cohen G (1993) Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 61: 1470–1478
Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (1993) Advances in neurology, vol 60. Raven Press, New York, pp 259–262
Steece-Collier K, Collier TJ, Sladek JR Jr (1990) Chronic levodopa impairs morphological development of grafted dopamine neurons. Exp Neurol 110: 201–208
Yahr MD (1987) Advances in neurology, vol 45. Raven Press, New York, pp 277–283
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Merchant, C.A., Cohen, G., Mytilineou, C. et al. Human transplacental transfer of carbidopa/levodopa. J Neural Transm Gen Sect 9, 239–242 (1995). https://doi.org/10.1007/BF02259664
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02259664